This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F12%3A11583%21RIV13-MZ0-00064165/
n11http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F12%3A11583%21RIV13-MZ0-00064165
rdf:type
n11:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1179/1743132812Y.0000000090
dcterms:description
Objectives: To evaluate safety and efficacy of add-on low-dose azathioprine or interferon (IFN)-beta in patients with active multiple sclerosis despite monotherapy. Methods: This retrospective observational study evaluated 5-year data from 85 patients with active multiple sclerosis despite monotherapy with either IFN-beta or azathioprine, who received add-on azathioprine or IFN-beta, respectively. In a subgroup of 23 patients, 10-year data were analysed. Clinical (relapse frequency, disability) and laboratory effects were compared preceding and following the addition of second drug and between the two treatment regimens. Potential serious adverse events were evaluated. Results: The add-on treatment triggered a drop in annualised relapse rate by approximately 1.5 points sustained over 5 and 10 years. No effect on disability was observed. Simultaneously, white blood cell and lymphocyte counts decreased, being below the physiological levels in 8-26% and 13-52% of patients at each time point, respectively. The drop in relapse rate was independent from the dosage of azathioprine or changes in lymphocyte count. Comparison between the two treatment regimens showed that, with the exception of lymphocyte count, these effects were triggered by the add-on of interferon but not azathioprine. The combination therapy was well tolerated; however, after 5 years on treatment a moderately increased incidence of cancer was observed. Conclusions: IFN-beta as add-on to azathioprine decreases relapse activity in active multiple sclerosis. In contrast, azathioprine add-on in patients with suboptimal response to IFN-beta does not improve the control over the disease activity. Objectives: To evaluate safety and efficacy of add-on low-dose azathioprine or interferon (IFN)-beta in patients with active multiple sclerosis despite monotherapy. Methods: This retrospective observational study evaluated 5-year data from 85 patients with active multiple sclerosis despite monotherapy with either IFN-beta or azathioprine, who received add-on azathioprine or IFN-beta, respectively. In a subgroup of 23 patients, 10-year data were analysed. Clinical (relapse frequency, disability) and laboratory effects were compared preceding and following the addition of second drug and between the two treatment regimens. Potential serious adverse events were evaluated. Results: The add-on treatment triggered a drop in annualised relapse rate by approximately 1.5 points sustained over 5 and 10 years. No effect on disability was observed. Simultaneously, white blood cell and lymphocyte counts decreased, being below the physiological levels in 8-26% and 13-52% of patients at each time point, respectively. The drop in relapse rate was independent from the dosage of azathioprine or changes in lymphocyte count. Comparison between the two treatment regimens showed that, with the exception of lymphocyte count, these effects were triggered by the add-on of interferon but not azathioprine. The combination therapy was well tolerated; however, after 5 years on treatment a moderately increased incidence of cancer was observed. Conclusions: IFN-beta as add-on to azathioprine decreases relapse activity in active multiple sclerosis. In contrast, azathioprine add-on in patients with suboptimal response to IFN-beta does not improve the control over the disease activity.
dcterms:title
Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis
skos:prefLabel
Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis
skos:notation
RIV/00064165:_____/12:11583!RIV13-MZ0-00064165
n11:predkladatel
n13:ico%3A00064165
n3:aktivita
n7:Z n7:I n7:S
n3:aktivity
I, S, Z(MSM0021620849)
n3:cisloPeriodika
10
n3:dodaniDat
n6:2013
n3:domaciTvurceVysledku
n9:5387345 n9:8895465 n9:2810646
n3:druhVysledku
n12:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
142378
n3:idVysledku
RIV/00064165:_____/12:11583
n3:jazykVysledku
n16:eng
n3:klicovaSlova
Add-on therapy; Cancer; Disability; Interferon; Relapse rate; placebo-controlled trial; combination therapy; double-blind; ms; multicenter; efficacy; cancer; risk; corticosteroids
n3:klicoveSlovo
n4:Relapse%20rate n4:Cancer n4:cancer n4:double-blind n4:ms n4:multicenter n4:risk n4:placebo-controlled%20trial n4:combination%20therapy n4:efficacy n4:Disability n4:Add-on%20therapy n4:Interferon n4:corticosteroids
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[56786D352D33]
n3:nazevZdroje
Neurological Research
n3:obor
n18:FH
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
3
n3:rokUplatneniVysledku
n6:2012
n3:svazekPeriodika
34
n3:tvurceVysledku
Havrdová, Eva Tichá, Veronika Kalinčík, Tomáš
n3:wos
000311029600002
n3:zamer
n14:MSM0021620849
s:issn
0161-6412
s:numberOfPages
8